Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

被引：0
|
作者：
Lennart Tonneijck
Mark M. Smits
Marcel H. A. Muskiet
Trynke Hoekstra
Mark H. H. Kramer
A. H. Jan Danser
Michaela Diamant
Jaap A. Joles
Daniël H. van Raalte
机构：
[1] VU University Medical Center Amsterdam,Department of Internal Medicine/Diabetes Center
[2] VU University Amsterdam,Department of Health Sciences and the EMGO Institute for Health and Care Research
[3] VU University Medical Center,Department of Epidemiology and Biostatistics
[4] Erasmus University Medical Center,Division of Pharmacology and Vascular Medicine, Department of Internal Medicine
[5] University Medical Center,Department of Nephrology and Hypertension
来源：
Diabetologia | 2016年 / 59卷
关键词：
Diabetes; Exenatide; Glomerular filtration rate; Glomerular hyperfiltration; GLP-1 receptor agonist; Glucagon-like peptide-1; Renal function; Renal haemodynamics; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1412 / 1421
页数：9
相关论文
共 50 条
  • [1] Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
    Tonneijck, Lennart
    Smits, Mark M.
    Muskiet, Marcel H. A.
    Hoekstra, Trynke
    Kramer, Mark H. H.
    Danser, A. H. Jan
    Diamant, Michaela
    Joles, Jaap A.
    van Raalte, Daniel H.
    DIABETOLOGIA, 2016, 59 (07) : 1412 - 1421
  • [2] Effects of prebiotics on postprandial GLP-1, GLP-2 and glucose regulation in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled crossover trial
    Birkeland, Eline
    Gharagozlian, Sedegheh
    Gulseth, Hanne L.
    Birkeland, Kare, I
    Hartmann, Bolette
    Holst, Jens J.
    Holst, Rene
    Aas, Anne-Marie
    DIABETIC MEDICINE, 2021, 38 (10)
  • [3] Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Tonneijck, Lennart
    Smits, Mark M.
    Muskiet, Marcel H. A.
    Hoekstra, Trynke
    Kramer, Mark H. H.
    Danser, A. H. Jan
    ter Wee, Piet M.
    Diamant, Michaela
    Joles, Jaap A.
    van Raalte, Daniel H.
    DIABETES CARE, 2016, 39 (11) : 2042 - 2050
  • [4] Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial
    Smits, Mark M.
    Tonneijck, Lennart
    Muskiet, Marcel H. A.
    Hoekstra, Trynke
    Kramer, Mark H. H.
    Diamant, Michaela
    van Raalte, Daniel H.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2017, 176 (01) : 77 - 86
  • [5] Acute Renal Effects of GLP-1 Receptor Agonist Exenatide in Healthy Overweight Males
    Muskiet, Marcel H.
    Tonneijck, Lennart
    Smits, Mark M.
    Joles, Jaap A.
    Kramer, Mark H.
    Diamant, Michaela
    Van Raalte, Daniel H.
    DIABETES, 2015, 64 : A153 - A153
  • [6] Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
    Roux, Carel W. le
    Steen, Oren
    Lucas, Kathryn J.
    Startseva, Elena
    Unseld, Anna
    Hennige, Anita M.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (03): : 162 - 173
  • [7] Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
    Ratner, R. E.
    Rosenstock, J.
    Boka, G.
    DIABETIC MEDICINE, 2010, 27 (09) : 1024 - 1032
  • [8] Renal Effects of 12-Week GLP-1 Receptor Agonist Liraglutide or DPP-4 Inhibitor Sitagliptin Treatment in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
    Tonneijck, Lennart
    Smits, Mark M.
    Muskiet, Marcel H.
    Hoekstra, Trynke
    Kramer, Mark H. H.
    Diamant, Michaela
    Joles, Jaap A.
    Van Raalte, Daniel H.
    DIABETES, 2016, 65 : A140 - A140
  • [9] Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial
    Laursen, Jens Christian
    Sondergaard-Heinrich, Niels
    de Melo, Joana Mendes Lopes
    Haddock, Bryan
    Rasmussen, Ida Kirstine Bull
    Safavimanesh, Farzaneh
    Hansen, Christian Stevns
    Storling, Joachim
    Larsson, Henrik Bo Wiberg
    Groop, Per-Henrik
    Frimodt-Moller, Marie
    Andersen, Ulrik Bjorn
    Rossing, Peter
    ECLINICALMEDICINE, 2021, 37
  • [10] Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled crossover trial
    Laursen, J. C.
    Heinrich, N. Sondergaard
    de Melo, J. M. L.
    Haddock, B.
    Rasmussen, I. K. B.
    Safavimanesh, F.
    Hansen, C. Stevns
    Storling, J.
    Larsson, H. B. Wiberg
    Groop, P. -H.
    Frimodt-Moller, M.
    Andersen, U. B.
    Rossing, P.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 121 - 121
12345